



Molecular Minimal Residual Disease (MRD) monitoring based on IG/TR and BCR/ABL1 analysis and their prognostic value in patients treated in the EsPhALL study with imatinib



128 EsPhALL patients

•  Imatinib

•  MRD detection by real-time PCR of **IG/TR** and **BCR/ABL1**



IG/TR MRD

Number of patients
MRD negativity



BCR/ABL1 MRD

Number of patients
MRD negativity



- Overall concordance between the two methods: 69%
- IG/TR MRD monitoring is more reliable
- The earlier MRD negativity is achieved, the better the prognosis